Prosensa Raises Series A

Prosensa Holding BV, a Dutch biotech company focused on RNA interference therapeutics using exon skipping technology, has raised $18 million in Series A funding. Abingworth Management and Life Science Partners co-led the deal, and were joined by return backer Medsciences Capital. www.prosensa.eu